ADMA Biologics
ADMA
ADMA Biologics (ADMA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.16
- EPS estimate
- $0.16
- EPS surprise
- +0.98%
- Revenue surprise
- −0.76%
- Revenue
- $124.4M
- Revenue estimate
- $125.3M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.16 | $0.16 | +0.98% | $124.4M | SEC |
| Q1 2026 | May 6, 2026 | $0.19 | $0.17 | −11.74% | $114.5M | SEC |
| Q4 2025 | Feb 25, 2026 | $0.19 | $0.21 | +15.24% | $139.2M | SEC |
| Q3 2025 | Nov 5, 2025 | $0.15 | $0.16 | +9.43% | $134.2M | SEC |
| Q2 2025 | Aug 6, 2025 | $0.14 | $0.15 | +7.75% | $122.0M | SEC |
| Q1 2025 | May 7, 2025 | $0.15 | $0.14 | −11.22% | $114.8M | SEC |
| Q4 2024 | Mar 3, 2025 | $0.15 | $0.14 | −6.07% | $117.5M | SEC |
| Q3 2024 | Nov 7, 2024 | $0.13 | $0.16 | +25.38% | $119.8M | SEC |
| Q2 2024 | Aug 8, 2024 | $0.08 | $0.14 | +77.25% | $107.2M | SEC |
| Q1 2024 | May 9, 2024 | $0.06 | $0.09 | +62.00% | $81.9M | SEC |
| Q4 2023 | Feb 28, 2024 | $0.03 | −$0.08 | −420.00% | $73.9M | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.01 | $0.01 | +233.33% | $67.3M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.03 | −$0.02 | +29.60% | $60.1M | SEC |
| Q1 2023 | May 10, 2023 | −$0.04 | −$0.03 | +29.41% | $56.9M | SEC |
| Q4 2022 | Mar 23, 2023 | −$0.07 | −$0.06 | +14.29% | $50.0M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.08 | −$0.08 | −3.23% | $41.1M | SEC |
| Q2 2022 | Aug 10, 2022 | −$0.08 | −$0.07 | +12.50% | $33.9M | SEC |
| Q1 2022 | May 11, 2022 | −$0.09 | −$0.13 | −52.94% | $29.1M | SEC |
| Q4 2021 | Mar 24, 2022 | −$0.09 | −$0.09 | +2.91% | $26.4M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.14 | −$0.13 | +6.00% | $20.7M | SEC |
Quarterly revenue
Frequently asked questions
When did ADMA Biologics (ADMA) last report earnings?
ADMA Biologics last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did ADMA beat earnings estimates?
Yes. ADMA Biologics reported EPS of $0.16 for Q2 2026 against a $0.16 estimate — a 0.98% beat.
How much revenue did ADMA report last quarter?
ADMA Biologics reported $124.4M in revenue for Q2 2026, against a consensus estimate of $125.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.